Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0K8NW
|
||||
| Former ID |
DNC001217
|
||||
| Drug Name |
Ritanserin
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Anxiety disorder [ICD9: 300, 311; ICD10:F32, F40-F42] | Discontinued in Phase 3 | [1], [2] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C27H25F2N3OS
|
||||
| InChI |
InChI=1S/C27H25F2N3OS/c1-18-24(26(33)32-16-17-34-27(32)30-18)12-15-31-13-10-21(11-14-31)25(19-2-6-22(28)7-3-19)20-4-8-23(29)9-5-20/h2-9,16-17H,10-15H2,1H3
|
||||
| InChIKey |
JUQLTPCYUFPYKE-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 87051-43-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
855736, 7379883, 8149992, 8153123, 11111716, 11335367, 11360606, 11364744, 11367306, 11369868, 11372124, 11378033, 11461578, 11485176, 11489376, 11490838, 11495644, 12013534, 14834621, 17405639, 24278117, 26680887, 29224143, 47207399, 47216659, 47885282, 47959597, 48334360, 50057747, 50100336, 50104035, 50104036, 50104037, 50123110, 53301609, 53778189, 53788831, 56311639, 56423112, 57322596, 85089208, 85209702, 85231205, 85789270, 90340705, 91011597, 92303281, 92307929, 99301280, 103025197
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2B receptor | Target Info | Antagonist | [3] | |
| 5-hydroxytryptamine 2A receptor | Target Info | Antagonist | [4], [5], [3] | ||
| 5-hydroxytryptamine 2 receptor | Target Info | Antagonist | [6], [7], [8], [5] | ||
| 5-hydroxytryptamine receptor | Target Info | Antagonist | [6] | ||
| 5-hydroxytryptamine 2C receptor | Target Info | Antagonist | [6], [7], [8], [5] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channelshsa04020:Calcium signaling pathway | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (q) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling | |||||
| SIDS Susceptibility Pathways | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 97). | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000237) | ||||
| REF 3 | p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. Eur J Pharmacol. 1998 Oct 23;359(2-3):185-90. | ||||
| REF 4 | Human embryonic stem cell-derived oligodendrocyte progenitor cells express the serotonin receptor and are susceptible to JC virus infection. J Virol. 2008 Sep;82(17):8896-9. Epub 2008 Jun 25. | ||||
| REF 5 | Characterization of contractile 5-hydroxytryptamine receptor subtypes in the in situ autoperfused kidney in the anaesthetized rat. Eur J Pharmacol. 2008 Sep 11;592(1-3):133-7. Epub 2008 Jul 4. | ||||
| REF 6 | Combined treatment of portal hypertension with ritanserin and propranolol in conscious and unrestrained cirrhotic rats. Hepatology. 1992 May;15(5):878-82. | ||||
| REF 7 | Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. Behav Pharmacol. 2008 Mar;19(2):145-52. | ||||
| REF 8 | Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo. J Psychiatr Res.2008 Sep;42(11):894-901. Epub 2008 Jun 3. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.